 REHOVOT, Israel, Oct. 11, 2021 PRNewswire -- CollPlant Biotechnologies Nasdaq: CLGN, a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that its recombinant human collagen rhCollagen-based bioink was used successfully by researchers from Israels Technion Institute of Technology to create a 3D bioprinted implantable tissue containing a network of blood vessels capable of supplying blood to the implanted tissue. We are excited with the impressive and innovative work of our collaborators at the Technion, said Yehiel Tal, CollPlants CEO. 